|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The progesterone receptor gene, which is mapped to chromosome 11 at band q21-23, was not amplified in these esophageal carcinomas.
|
2529025 |
1989 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Carcinomas in the under 30 years age group had a lower incidence of oestrogen and progesterone receptor positivity.
|
8956795 |
1996 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Carcinomas associated with Recurrence Score ≥18 showed lower progesterone receptor immunoreactivity, increased stromal cellularity and presence of inflammatory cells associated with the tumor.
|
22173289 |
2012 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, ER and PR were expressed in 42 (66%) and 42 (66%) carcinomas, respectively, and in neither of the 2 phyllode tumors.
|
16211220 |
2005 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Carcinomas with polysomy 17 were associated with adverse histological indicators including high histological grade, high nuclear grade, poor Nottingham Prognostic Index, advanced local tumour extent and progesterone receptor negativity.
|
23908451 |
2013 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Three of the 5 PTEN immunostain-negative carcinomas were also both estrogen and progesterone receptor-negative, whereas only 5 of 22 of the PTEN-positive group were double receptor-negative.
|
10514407 |
1999 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PPARgamma immunoreactivity was detected in 42% of carcinomas, and was significantly associated with the status of estrogen receptor (ER) alpha, ERbeta, progesterone receptor, retinoic X receptors, p21 or p27, and negatively correlated with histological grade or cyclooxygenase-2 status.
|
16601291 |
2006 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Among patients with LM332 β3-expressing and ER/PgR-negative carcinomas, 10-year survival was significantly reduced (P < .0450).
|
30125583 |
2018 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We examined ER and progesterone receptor via immunohistochemistry in tubular (N = 27), mixed ductal/tubular (N = 16), and well-differentiated ductal (N = 27) carcinomas with comparison to surrounding normal breast tissue.
|
25357113 |
2014 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nuclear expression of estrogen and progesterone receptors was increased in both indolent and aggressive neoplasms, but was without sex- or age-related differences; however, whereas progesterone receptor expression was diffuse and strong in clinically indolent carcinomas, its expression was diminished in aggressive neoplasms.
|
21358618 |
2011 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile.
|
20208479 |
2010 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A higher percentage of comedo-invasive carcinomas demonstrated aneuploidy 71%; p = 0.0158), elevated levels of S-phase fraction (75%; p = 0.0016) and Ki-67 staining (55%; p = 0.0512), overexpression of HER-2/neu oncogene (47%; p = 0.0011), and were ER negative (35%; p = 0.0148), PR negative (47%; p = 0.0073) when compared to noncomedo-invasive carcinomas.
|
7496840 |
1995 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A good pathological response, defined as a pathological complete response or residual isolated invasive tumor cells, was found significantly more frequently for estrogen (ER) and progesterone receptor (PR) negative breast carcinomas compared to ER and PR positive and ER or PR positive carcinomas, respectively (43.5 vs. 37.5 and 10.3 %, p = 0.006), and was significantly associated with high tumor grade (G3) (p = 0.002).
|
22903472 |
2012 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of OR-α and PR was significantly lower in circumanal gland carcinomas than in circumanal gland adenomas.
|
30060844 |
2018 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, there are two distinct major pathways to the evolution of low- and high-grade invasive carcinomas: whilst the former consistently show oestrogen receptor (ER) and progesterone receptor (PgR) positivity and 16q loss, the latter are usually ER/PgR-negative and show Her-2 overexpression/amplification and complex karyotypes.
|
15641021 |
2005 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mean ER and PR levels were highest in hyperplastic lesions, especially those with atypical features, whereas carcinomas of all grades had significantly lower values.
|
8491764 |
1993 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Eighteen of 58 (31%) carcinomas were estrogen receptor positive and 22 (38%) were positive for progesterone receptor.
|
7919121 |
1994 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Subsequent comparison between 20 carcinomas using AFM220xe5, with and without LOH in terms of pathological parameters showed significant associations with differences in age (P = 0.04) ER (P = 0.05) Ki-67 (P = 0.04) and PR (P = 0.01) a trend toward significance was found for tumor size (P = 0.06) and histological grade III (P = 0.06).
|
15183540 |
2004 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Infiltrating lobular carcinoma had a higher ER positivity between groups (85.7%), whereas noninvasive carcinomas had a higher PR positivity (67%).
|
26266392 |
2015 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We compared our findings with conventional clinicopathological indicators [menopausal status, number of axillary nodes, histological grade, tumor size and type, estrogen receptor (ER), and progesterone receptor] and with p53 protein expression. bcl-2 protein was present in 65% of the carcinomas (117/180) and it was significantly associated with ER and progesterone receptor and inversely associated with p53 in both the groups of patients treated with adjuvant chemotherapy and tamoxifen.
|
9815973 |
1995 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
93.5% of the p53 immunopositive carcinomas were ER-negative, and in 95.7% of this subclass of patients no PgR could be detected.
|
11299837 |
2001 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Quantitative real-time polymerase chain reaction demonstrated that ER alpha, ER beta and PR were statistically elevated by 3-, 4- and 8-fold in carcinomas compared with normal mammary glands.
|
15637090 |
2005 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In carcinomas GH mRNA was also found in progesterone receptor-negative tissue samples, indicating that after malignant transformation GH gene expression may become progestin independent.
|
7738169 |
1995 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quantitatively increased nm23-H1 immunopositive staining was more frequently observed in special histologic types of infiltrating cancers, in high nuclear grade tumors, as well as in carcinomas with high PgR levels (p = 0.05).
|
10403901 |
1999 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Forty-two pure salivary duct carcinomas, 35 of which contained an in-situ component as defined by histological review and/or immunohistochemical analysis, were stained with antibodies for oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6.
|
22882517 |
2012 |